Product Pathways - Protein Stability
AMFR Antibody #9590
|9590S||100 µl (10 western blots)||---||In Stock||---|
|9590||carrier free and custom formulation / quantity||email request|
Already purchased this product? Write a Review.
|W||1:1000||Human, Monkey, Dog||Endogenous||75||Rabbit|
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting, IP=Immunoprecipitation
Specificity / Sensitivity
AMFR Antibody recognizes endogenous levels of total AMFR protein. This antibody does not cross-react with HRD1.
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human AMFR protein. Antibodies are purified by protein A and peptide affinity chromatography.
Autocrine motility factor receptor (AMFR/gp78) is a putative seven transmembrane domain G protein-coupled receptor that functions, in part, at the cell surface as a cytokine receptor for autocrine motility factor/phosphoglucose isomerase (AMF/PGI). AMFR is also localized to an intracellular mitochondria-associated smooth ER domain where it functions as an E3 ubiquitin ligase (1). AMFR function, as both a cytokine receptor and ubiquitin ligase, is linked to a variety of cellular signaling cascades associated with metastasis development and increased invasiveness. AMFR was initially proposed to be a RING-H2 E3 ubiquitin ligase after sequence analysis identified a catalytic RING finger and CUE motif, which are responsible for ubiquitin ligase activity and ubiquitin binding, respectively (2,3). Indeed, AMFR is a key component and amongst the best characterized ubiquitin ligases of the endoplasmic reticulum associated degradation (ERAD) machinery, a process involving recognition of misfolded proteins, ubiquitination, deglycosylation, retro-translocation to the cytosol, and targeting to the proteasome (4). Recent studies have shown that AMFR plays an important role in cholesterol homeostasis via the sterol-mediated ubiquitination of HMG-CoA reductase and its cofactor Insig-1 (5,6). Furthermore, AMFR has been implicated in the degradation of apolipoprotein B100 (7). It was recently reported that AMFR degrades the metastasis suppressor KAI-1/CD-82, representing the first evidence that AMFR ubiquitin ligase activity is involved in metastasis development (8). Increased expression of AMFR correlates with a high incidence of recurrence and reduced survival in patients with bladder, colorectal, and gastric cancers (9-11).
- Registre, M. et al. (2004) Biochem Biophys Res Commun 320, 1316-22.
- Shimizu, K. et al. (1999) FEBS Lett 456, 295-300.
- Ponting, C.P. (2000) Biochem J 351 Pt 2, 527-35.
- Meusser, B. et al. (2005) Nat Cell Biol 7, 766-72.
- Song, B.L. et al. (2005) Mol Cell 19, 829-40.
- Lee, J.N. et al. (2006) J Biol Chem 281, 39308-15.
- Liang, J.S. et al. (2003) J Biol Chem 278, 23984-8.
- Tsai, Y.C. et al. (2007) Nat Med 13, 1504-9.
- Hirono, Y. et al. (1996) Br J Cancer 74, 2003-7.
- Nakamori, S. et al. (1994) Cancer 74, 1855-62.
- Otto, T. et al. (1997) Am J Pathol 150, 1919-23.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.